<DOC>
	<DOCNO>NCT00550173</DOCNO>
	<brief_summary>The purpose study compare combination erlotinib pemetrexed versus either pemetrexed alone erlotinib alone , term progression-free survival ( time objective worsen disease ) patient never smoke locally advanced metastatic Nonsquamous Non-Small Cell Lung Cancer fail first-line chemotherapy treatment .</brief_summary>
	<brief_title>A Study Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients locally advance metastatic nonsquamous nonsmall cell lung cancer Patients must nonsmoker Patients must least one measurable lesion Performance status 0 2 Eastern Cooperative Oncology Group Scale Patients must fail one prior chemotherapy regimen must consider eligible chemotherapy follow progression disease . Patients receive treatment within last 30 day drug receive regulatory approval indication Patients previously receive treatment drug human epidermal growth factor receptor Patients previously receive treatment drug similar target Pemetrexed Patients know significant ophthalmologic abnormality surface eye Patients history severe hypersensitivity reaction erlotinib pemetrexed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>